Classification of Rhabdomyosarcoma and its molecular basis

Advances in Anatomic Pathology

Volumn 20, Issue 6, 2013, Pages 387-397

  Parham, David M ^a   Barr, Frederic G ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

classification systems; genetic testing; prognosis; rhabdomyosarcoma

Indexed keywords

TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7;

ALLELE; CHILDHOOD DISEASE; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DISEASE CLASSIFICATION; GENE; GENE AMPLIFICATION; GENE FUSION; GENE MUTATION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOLECULAR GENETICS; MUSCLE TUMOR; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHABDOMYOSARCOMA; WORLD HEALTH ORGANIZATION;

CHILD; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PAX7 TRANSCRIPTION FACTOR; PROGNOSIS; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; TRANSLOCATION, GENETIC;

EID: 84886558872     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3182a92d0d     Document Type: Review

References (97)

1. Parham DM, Alaggio R, Coffin CM. Myogenic tumors in children and adolescents. Pediatr Dev Pathol. 2012;15:211-238.
2. Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59:5-10.
3. Kodet R, Fajstavr J, Kabelka Z, et al. Is fetal cellular rhabdomyoma an entity or a differentiated rhabdomyosarcoma? A study of patients with rhabdomyoma of the tongue and sarcoma of the tongue enrolled in the intergroup rhabdomyosarcoma studies I, II, and III. Cancer. 1991;67: 2907-2913.
4. Cessna MH, Zhou H, Perkins SL, et al. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol. 2001;25:1150-1157. (Pubitemid 32777714)
5. Folpe AL. MyoD1 and myogenin expression in human neoplasia: a review and update. Adv Anat Pathol. 2002;9: 198-203.
6. Raney RB, Oberlin O, Parham DM. An English Translation of Joseph Luc Riopelle, MD, (Hotel-Dieu of Montreal), and Jean Paul Theriault (Hopital General of Verdun, Quebec, Canada): Sur une forme meconnue de sarcome des parties molles: le rhabdomyosarcome alveolaire (concerning an unrecognized form of sarcoma of the soft tissues: alveolar rhabdomyosarcoma). annales d'anatomie pathologique 1956;1:88-111. Pediatr Dev Pathol. 2012;15:407-416.
7. Stout AP. Rhabdomyosarcoma of the skeletal muscles. Ann Surg. 1946;123:447-472.
8. Horn RC Jr, Enterline HT. Rhabdomyosarcoma: a clinicopathological study and classification of 39 cases. Cancer. 1958;11:181-199.
9. Stout AP, Lattes R. Malignant tumors of muscle. In: Stout AP, Lattes R, eds. Atlas of Tumor Pathology Second Series: Tumors of the Soft Tissues. Washington, DC: Armed Forces Institute of Pathology; 1967:133-144.
10. Newton WA Jr, Soule EH, Hamoudi AB, et al. Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J Clin Oncol. 1988;6:67-75. (Pubitemid 18039993)
11. Gonzalez-Crussi F, Black-Schaffer S. Rhabdomyosarcoma of infancy and childhood. Problems of morphologic classification. Am J Surg Pathol. 1979;3:157-171. (Pubitemid 9148077)
12. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610-630.
13. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. Cancer. 1978;41:1937-1948. (Pubitemid 8335406)
14. Palmer NF, Foulkes M. Histopathology and prognosis in the second Intergroup Rhabdomyosarcoma Study (IRS II). Proc Int Soc Pediatr Oncol. 1983;2:229.
15. Palmer NF, Sachs N, Foulkes M. Histology and prognosis in rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study. Proc Int Soc Pediatr Oncol. 1981;13:113.
16. Palmer NF, Sachs N, Foulkes M. Histology and prognosis in rhabdomyosarcoma (IRS-I). Proc Am Soc Clin Oncol. 1982;1:170.
17. Tsokos M, Webber BL, Parham DM, et al. Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med. 1992;116:847-855.
18. Cavazzana AO, Schmidt D, Ninfo V, et al. Spindle cell rhabdomyosarcoma. A prognostically favorable variant of rhabdomyosarcoma. Am J Surg Pathol. 1992;16:229-235.
19. Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification-an Intergroup Rhabdomyosarcoma Study. Cancer. 1995;76:1073-1085.
20. Asmar L, Gehan EA, Newton WA, et al. Agreement among and within groups of pathologists in the classification of rhabdomyosarcoma and related childhood sarcomas. Report of an international study of four pathology classifications. Cancer. 1994;74:2579-2588. (Pubitemid 24320865)
21. Caillaud JM, Gerard-Marchant R, Marsden HB, et al. Histopathological classification of childhood rhabdomyosarcoma: a report from the International Society of Pediatric Oncology pathology panel. Med Pediatr Oncol. 1989;17: 391-400. (Pubitemid 19248190)
22. Hawkins DS, Spunt SL, Skapek SX. Children's Oncology Group's 2013 blueprint for research: soft tissue sarcomas. Pediatr Blood Cancer. 2013;60:1001-1008.
23. Mentzel T, Katenkamp D. Sclerosing, pseudovascular rhabdomyosarcoma in adults. Clinicopathological and immunohistochemical analysis of three cases. Virchows Arch. 2000;436: 305-311. (Pubitemid 30219226)
24. Folpe AL, McKenney JK, Bridge JA, et al. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma. Am J Surg Pathol. 2002;26:1175-1183. (Pubitemid 34969187)
25. Chiles MC, Parham DM, Qualman SJ, et al. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group. Pediatr Dev Pathol. 2004;7:583-594.
26. World Health Organization. WHO Classification of Tumours of Soft Tissue and Bone. Lyon: International Agency for Research on Cancer; 2013:134-135.
27. Stock N, Chibon F, Binh MB, et al. Adult-type rhabdomyosarcoma: analysis of 57 cases with clinicopathologic description, identification of 3 morphologic patterns and prognosis. Am J Surg Pathol. 2009;33:1850-1859.
28. Nascimento AF, Fletcher CD. Spindle cell rhabdomyosarcoma in adults. Am J Surg Pathol. 2005;29:1106-1113. (Pubitemid 41045557)
29. Kodet R, Newton WA Jr, Hamoudi AB, et al. Childhood rhabdomyosarcoma with anaplastic (pleomorphic) features. A report of the Intergroup Rhabdomyosarcoma Study. Am J Surg Pathol. 1993;17:443-453. (Pubitemid 23121774)
30. Qualman S, Lynch J, Bridge J, et al. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer. 2008;113:3242-3247.
31. Douglass EC, Valentine M, Etcubanas E, et al. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet. 1987;45:148-155. (Pubitemid 18024696)
32. Turc-Carel C, Lizard-Nacol S, Justrabo E, et al. Consistent chromosomal translocation in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet. 1986;19:361-362.
33. Wang-Wuu S, Soukup S, Ballard E, et al. Chromosomal analysis of sixteen human rhabdomyosarcomas. Cancer Res. 1988;48:983-987. (Pubitemid 18061898)
34. Biegel JA, Meek RS, Parmiter AH, et al. Chromosomal translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma. Genes Chromosomes Cancer. 1991;3:483-484.
35. Douglass EC, Rowe ST, Valentine M, et al. Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer. 1991;3:480-482.
36. Bridge JA, Liu J, Qualman SJ, et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer. 2002;33:310-321. (Pubitemid 34130938)
37. Pandita A, Zielenska M, Thorner P, et al. Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma. Neoplasia. 1999;1:262-275.
38. Weber-Hall S, Anderson J, McManus A, et al. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res. 1996;56:3220-3224. (Pubitemid 26242966)
39. Nishimura R, Takita J, Sato-Otsubo A, et al. Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array. Cancer Sci. 2013; 104:856-864.
40. Paulson V, Chandler G, Rakheja D, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer. 2011;50:397-408.
41. Williamson D, Missiaglia E, de Reynies A, et al. Fusion genenegative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol. 2010;28:2151-2158.
42. Duan F, Smith LM, Gustafson DM, et al. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group. Genes Chromosomes Cancer. 2012;51:662-674.
43. Barr FG, Duan F, Smith LM, et al. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Genes Chromosomes Cancer. 2009;48:661-672.
44. Reichek JL, Duan F, Smith LM, et al. Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Clin Cancer Res. 2011;17:1463-1473.
45. Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol. 2009;174:550-564.
46. Visser M, Sijmons C, Bras J, et al. Allelotype of pediatric rhabdomyosarcoma. Oncogene. 1997;15:1309-1314. (Pubitemid 27429747)
47. Koufos A, Hansen MF, Copeland NG, et al. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature. 1985;316:330-334. (Pubitemid 15237805)
48. Scrable HJ, Witte DP, Lampkin BC, et al. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature. 1987;329:645-647. (Pubitemid 17140118)
49. Ping AJ, Reeve AE, Law DJ, et al. Genetic linkage of Beckwith-Wiedemann syndrome to 11p15. Am J Hum Genet. 1989;44:720-723. (Pubitemid 19119984)
50. Weksberg R, Shuman C, Smith AC. Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet. 2005;137: 12-23. (Pubitemid 41113659)
51. Onyango P, Feinberg AP. A nucleolar protein, H19 opposite tumor suppressor (HOTS), is a tumor growth inhibitor encoded by a human imprinted H19 antisense transcript. Proc Natl Acad Sci USA. 2011;108:16759-16764.
52. Scrable H, Witte D, Shimada H, et al. Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer. 1989;1:23-35. (Pubitemid 20093336)
53. Felix CA, Kappel CC, Mitsudomi T, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 1992;52:2243-2247.
54. Gao Z, Zhang S, Yang G. A study of p16 gene and its protein expression in rhabdomyosarcoma. Zhonghua Bing Li Xue Za Zhi. 1998;27:290-293.
55. Stratton MR, Fisher C, Gusterson BA, et al. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 1989;49:6324-6327. (Pubitemid 20000931)
56. Shukla N, Ameur N, Yilmaz I, et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2012;18:748-757.
57. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;3:113-117. (Pubitemid 23079791)
58. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994;54:2869-2872. (Pubitemid 24187765)
59. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma [published erratum appears in Nat Genet 1994 Feb;6(2):214]. Nat Genet. 1993;5:230-235. (Pubitemid 23330384)
60. Barr FG, Nauta LE, Hollows JC. Structural analysis of PAX3 genomic rearrangements in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet. 1998;102:32-39. (Pubitemid 28129056)
61. Fitzgerald JC, Scherr AM, Barr FG. Structural analysis of PAX7 rearrangements in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet. 2000;117:37-40. (Pubitemid 30099653)
62. Bennicelli JL, Advani S, Schafer BW, et al. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene. 1999;18:4348-4356. (Pubitemid 29392375)
63. Bennicelli JL, Edwards RH, Barr FG. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA. 1996;93:5455-5459. (Pubitemid 26159471)
64. Davis RJ, Barr FG. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA. 1997;94:8047-8051. (Pubitemid 27343774)
65. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001;20: 5736-5746. (Pubitemid 32928111)
66. Mosquera JM, Sboner A, Zhang L, et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer. 2013;52: 538-550.
67. Sumegi J, Streblow R, Frayer RW, et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer. 2010;49:224-236.
68. Bourgeois JM, Knezevich SR, Mathers JA, et al. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol. 2000;24:937-946. (Pubitemid 30430481)
69. Calabrese G, Guanciali Franchi P, Stuppia L, et al. Translocation (8;11)(q12-13;q21) in embryonal rhabdomyosarcoma. Cancer Genet Cytogenet. 1992;58:210-211.
70. Sirvent N, Trassard M, Ebran N, et al. Fusion of EWSR1 with the DUX4 facioscapulohumeral muscular dystrophy region resulting from t(4;22)(q35;q12) in a case of embryonal rhabdomyosarcoma. Cancer Genet Cytogenet. 2009;195:12-18.
71. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol. 2002;20:2672-2679. (Pubitemid 34575640)
72. Barr FG, Nauta LE, Davis RJ, et al. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet. 1996;5:15-21. (Pubitemid 26018269)
73. Barr FG, Smith LM, Lynch JC, et al. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. J Mol Diagn. 2006;8:202-208. (Pubitemid 43811243)
74. de Alava E, Ladanyi M, Rosai J, et al. Detection of chimeric transcripts in desmoplastic small round cell tumor and related developmental tumors by reverse transcriptase polymerase chain reaction. A specific diagnostic assay. Am J Pathol. 1995;147:1584-1591.
75. Frascella E, Toffolatti L, Rosolen A. Normal and rearranged PAX3 expression in human rhabdomyosarcoma. Cancer Genet Cytogenet. 1998;102:104-109. (Pubitemid 28164925)
76. Dumont SN, Lazar AJ, Bridge JA, et al. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization. J Cancer Res Clin Oncol. 2012;138:213-220.
77. Barr FG, Qualman SJ, Macris MH, et al. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res. 2002;62:4704-4710.
78. Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res. 2004;64:5539-5545. (Pubitemid 39095545)
79. Liu J, Guzman MA, Pezanowski D, et al. FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma. Mod Pathol. 2011;24:1327-1335.
80. Davicioni E, Finckenstein FG, Shahbazian V, et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 2006;66:6936-6946. (Pubitemid 44197668)
81. Lae M, Ahn EH, Mercado GE, et al. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAXFKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol. 2007;212:143-151. (Pubitemid 46852092)
82. Wachtel M, Runge T, Leuschner I, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol. 2006;24:816-822. (Pubitemid 46622049)
83. Rudzinski ER, Teot LA, Anderson JR, et al. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the Children's Oncology Group. Am J Clin Pathol. 2013;140:82-90.
84. Parham DM, Qualman SJ, Teot L, et al. Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Am J Surg Pathol. 2007;31:895-901. (Pubitemid 47165143)
85. Parham DM, Shapiro DN, Downing JR, et al. Solid alveolar rhabdomyosarcomas with the t(2;13). Report of two cases with diagnostic implications. Am J Surg Pathol. 1994;18:474-478. (Pubitemid 24134088)
86. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol. 2009;27:5182-5188.
87. Nishio J, Althof PA, Bailey JM, et al. Use of a novel FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of alveolar rhabdomyosarcoma. Lab Invest. 2006;86:547-556. (Pubitemid 43780436)
88. Dias P, Chen B, Dilday B, et al. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol. 2000;156: 399-408. (Pubitemid 30643794)
89. Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA. 1999;96: 13264-13269.
90. Skapek SX, Anderson J, Barr FG, et al. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report. Pediatr Blood Cancer. 2013;60:1411-1417.
91. Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for intergroup rhabdomyosarcoma study V. J Pediatr Hematol Oncol. 2001;23:215-220. (Pubitemid 32524925)
92. Rubin BP, Nishijo K, Chen HIH, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell. 2011;19:177-191.
93. Shapiro DN, Parham DM, Douglass EC, et al. Relationship of tumor-cell ploidy to histologic subtype and treatment outcome in children and adolescents with unresectable rhabdomyosarcoma. J Clin Oncol. 1991;9:159-166.
94. Pappo AS, Crist WM, Kuttesch J, et al. Tumor-cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. The Intergroup Rhabdomyosarcoma Study Committee of the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 1993;11:1901-1905. (Pubitemid 23304614)
95. Kilpatrick SE, Teot LA, Geisinger KR, et al. Relationship of DNA ploidy to histology and prognosis in rhabdomyosarcoma. Comparison of flow cytometry and image analysis. Cancer. 1994;74:3227-3233. (Pubitemid 24375081)
96. Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the intergroup rhabdomyosarcoma study group. J Clin Oncol. 1999;17:3487-3493. (Pubitemid 29517919)
97. Wexler LH, Ladanyi M. Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation. J Clin Oncol. 2010;28:2126-2128.